Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655680 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT01655680 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 432 participants.
The verdict
NCT01655680, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
Interventions
- DRUG Placebo
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655680
The ClinicalTrials.gov registry entry for NCT01655680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01655680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01655680 about?
NCT01655680 is a clinical study titled "A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia". This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
What is the current status of trial NCT01655680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2012-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01655680?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01655680?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.